(Q37714905)

22 August 2017

1 reference

title

Liver X receptor modulators: a review of recently patented compounds (2007 - 2009). (English)

1 reference

22 August 2017

0 references

Xiaolin Li

1

1 reference

22 August 2017

Vince Yeh

series ordinal

2

1 reference

22 August 2017

Valentina Molteni

series ordinal

3

1 reference

22 August 2017

language of work or name

English

0 references

publication date

1 April 2010

1 reference

Expert Opinion on Therapeutic Patents

22 August 2017

published in

1 reference

22 August 2017

volume

20

1 reference

22 August 2017

issue

4

1 reference

22 August 2017

page(s)

535-562

1 reference

LXRS and FXR: the yin and yang of cholesterol and fat metabolism

22 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543771003621269

Liver X Receptor Signaling Pathways in Cardiovascular Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543771003621269

Reciprocal regulation of inflammation and lipid metabolism by liver X receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543771003621269

Role of LXRs in control of lipogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543771003621269

SREBPs: transcriptional mediators of lipid homeostasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543771003621269

Direct and indirect mechanisms for regulation of fatty acid synthase gene expression by liver X receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543771003621269

Stimulation of lipogenesis by pharmacological activation of the liver X receptor leads to production of large, triglyceride-rich very low density lipoprotein particles

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543771003621269

Synthetic LXR agonists increase LDL in CETP species

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543771003621269

Liver X receptor agonists as potential therapeutic agents for dyslipidemia and atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543771003621269

Different roles of liver X receptor alpha and beta in lipid metabolism: effects of an alpha-selective and a dual agonist in mice deficient in each subtype

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543771003621269

N-Acylthiadiazolines, a new class of liver X receptor agonists with selectivity for LXRbeta.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543771003621269

Antiatherosclerotic effects of a novel synthetic tissue-selective steroidal liver X receptor agonist in low-density lipoprotein receptor-deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543771003621269

Synthetic LXR agonist attenuates plaque formation in apoE-/- mice without inducing liver steatosis and hypertriglyceridemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543771003621269

Gene-selective modulation by a synthetic oxysterol ligand of the liver X receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543771003621269

Safety, pharmacokinetics, and pharmacodynamics of single doses of LXR-623, a novel liver X-receptor agonist, in healthy participants.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543771003621269

Liver X receptor activation enhances cholesterol loss from the brain, decreases neuroinflammation, and increases survival of the NPC1 mouse.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543771003621269

Liver X receptor agonist T0901317 reduces atherosclerotic lesions in apoE-/- mice by up-regulating NPC1 expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543771003621269

The effect of T0901317 on ATP-binding cassette transporter A1 and Niemann-Pick type C1 in apoE-/- mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543771003621269

Inactivation of liver X receptor beta leads to adult-onset motor neuron degeneration in male mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543771003621269

Liver X receptor beta (LXRbeta): a link between beta-sitosterol and amyotrophic lateral sclerosis-Parkinson's dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543771003621269

Role of LXR and ABCA1 in the pathogenesis of Alzheimer's disease - implications for a new therapeutic approach.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543771003621269

Attenuation of neuroinflammation and Alzheimer's disease pathology by liver x receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543771003621269

The role of cholesterol and statins in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543771003621269

Alzheimer's disease: the cholesterol connection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543771003621269

A fluid connection: cholesterol and Abeta

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543771003621269

ApoE 4 reduces the expression of Abeta degrading enzyme IDE by activating the NMDA receptor in hippocampal neurons.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543771003621269

Greasing the wheels of Abeta clearance in Alzheimer's disease: the role of lipids and apolipoprotein E.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543771003621269

ApoE promotes the proteolytic degradation of Abeta

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543771003621269

Impact of apolipoprotein E (ApoE) polymorphism on brain ApoE levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543771003621269

Deletion of Abca1 increases Abeta deposition in the PDAPP transgenic mouse model of Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543771003621269

The LXR agonist TO901317 selectively lowers hippocampal Abeta42 and improves memory in the Tg2576 mouse model of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543771003621269

The liver X receptor ligand T0901317 decreases amyloid beta production in vitro and in a mouse model of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543771003621269

Expression profiling in APP23 mouse brain: inhibition of Abeta amyloidosis and inflammation in response to LXR agonist treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543771003621269

Liver X receptor agonist regulation of Th17 lymphocyte function in autoimmunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543771003621269

Apoptotic cells promote their own clearance and immune tolerance through activation of the nuclear receptor LXR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543771003621269

Indazole-based liver X receptor (LXR) modulators with maintained atherosclerotic lesion reduction activity but diminished stimulation of hepatic triglyceride synthesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543771003621269

Discovery and SAR of cinnolines/quinolines as liver X receptor (LXR) agonists with binding selectivity for LXRbeta.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543771003621269

Carboxylic acid based quinolines as liver X receptor modulators that have LXRbeta receptor binding selectivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543771003621269

Biarylether amide quinolines as liver X receptor agonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543771003621269

4-(3-aryloxyaryl)quinoline alcohols are liver X receptor agonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543771003621269

4-(3-Aryloxyaryl)quinoline sulfones are potent liver X receptor agonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543771003621269

Quinoline-3-carboxamide containing sulfones as liver X receptor (LXR) agonists with binding selectivity for LXRbeta and low blood-brain penetration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543771003621269

1-(3-Aryloxyaryl)benzimidazole sulfones are liver X receptor agonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543771003621269

3-(3-Aryloxyaryl)imidazo[1,2-a]pyridine sulfones as liver X receptor agonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543771003621269

Synthetic LXR ligand inhibits the development of atherosclerosis in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543771003621269

Identification of macrophage liver X receptors as inhibitors of atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543771003621269

X-ray crystal structure of the liver X receptor beta ligand binding domain: regulation by a histidine-tryptophan switch

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543771003621269

Ligand activation of LXR beta reverses atherosclerosis and cellular cholesterol overload in mice lacking LXR alpha and apoE

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543771003621269

10.1517/13543771003621269

21 January 2018

Identifiers

DOI

1 reference

22 August 2017

1 reference